Imugene appoints experienced industry executive as new chief financial officer

Latest News

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Mike Tonroe as its chief financial officer (CFO).

Mr Tonroe is expected to commence in the newly-created in-house role in early September.

Mr Tonroe has extensive experience as a CFO and company secretary within the biopharmaceutical industry and also brings international finance leadership experience having worked in the US, Canada, UK and Hong Kong, in addition to Australia.

Most recently, Mr Tonroe was CFO and company secretary at ASX and NASDAQ-listed Genetic Technologies and Opthea. He previously served in the same role for Australian Synchotron Company.

Imugene managing director and CEO Leslie Chong said, “We've undertaken an extensive search recently to fill this important role within the business, with a view to finding someone that fits both in terms of expertise and the stage of the business, but also suits the culture at Imugene which we take great pride in. Mike is an outstanding appointment on these fronts and we are eager to see the positive impact his contribution will make to Imugene and the team.”